Xichun Hu
- Oncology top 5%
- HER2/EGFR in Cancer Research 40
- Cancer Treatment and Pharmacology 28
- Cancer Immunotherapy and Biomarkers 7
-
- Advanced Breast Cancer Therapies 35
- Lung Cancer Treatments and Mutations 10
- Genetics top 10%
- Cancer Research top 10%
- Breast Cancer Treatment Studies 10
- Cancer Genomics and Diagnostics 6
-
- Monoclonal and Polyclonal Antibodies Research 12
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Xichun Hu
80 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 891
- Pulmonary and Respiratory Medicine 518
- Genetics 142
- Cancer Research 189
- Radiology, Nuclear Medicine and Imaging 260
Countries citing papers authored by Xichun Hu
This map shows the geographic impact of Xichun Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xichun Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xichun Hu more than expected).
Fields of papers citing papers by Xichun Hu
This network shows the impact of papers produced by Xichun Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xichun Hu. The network helps show where Xichun Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xichun Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).breakdown → | 2024 | 52 |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 36 | |
| 8 | 2023 | 26 | |
| 9 | 2023 | 0 | |
| 10 | 2022 | 8 | |
| 11 | 2022 | 11 | |
| 12 | 2021 | 28 | |
| 13 | 2020 | 3 | |
| 14 | 2020 | 34 | |
| 15 | 2019 | 247 | |
| 16 | 2019 | 10 | |
| 17 | 2019 | 6 | |
| 18 | 2016 | 49 | |
| 19 | 2011 | 26 | |
| 20 | 2007 | 29 |
About Xichun Hu
Xichun Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 86 papers that have together received 1.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (40 papers), Advanced Breast Cancer Therapies (35 papers), Cancer Treatment and Pharmacology (28 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), Lung Cancer Treatments and Mutations (10 papers), Breast Cancer Treatment Studies (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Oncology (891 citations), Pulmonary and Respiratory Medicine (518 citations) and Genetics (142 citations). Xichun Hu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Zhongsheng Tong, Biyun Wang, Xiaoyu Zhu, Jianjun Zou, Zefei Jiang, Shusen Wang, Wěi Li, Fei Ma, Huiping Li and Binghe Xu. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.